Subcutaneous to intravenous prostacyclin analog transition in pulmonary hypertension

about

A systematic review of transition studies of pulmonary arterial hypertension specific medications Beyond the evidence: treating pulmonary hypertension in the intensive care unit.

P2860

Q33788548-4E74B384-166E-40FB-AAE4-D5AB27AB7726 Q42145097-76A83C59-4E27-4731-B199-93926B0A39DA

P2860

Subcutaneous to intravenous prostacyclin analog transition in pulmonary hypertension

Item

http://www.wikidata.org/entity/Q36325779

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Subcutaneous to intravenous prostacyclin analog transition in pulmonary hypertension

@ast

Subcutaneous to intravenous prostacyclin analog transition in pulmonary hypertension

@en

type

Item

label

Subcutaneous to intravenous prostacyclin analog transition in pulmonary hypertension

@ast

Subcutaneous to intravenous prostacyclin analog transition in pulmonary hypertension

@en

prefLabel

Subcutaneous to intravenous prostacyclin analog transition in pulmonary hypertension

@ast

Subcutaneous to intravenous prostacyclin analog transition in pulmonary hypertension

@en

P1476

Subcutaneous to intravenous prostacyclin analog transition in pulmonary hypertension

@en

P2093

Laith Alkukhun

http://www.w3.org/2001/XMLSchema#string

Nancy D Bair

http://www.w3.org/2001/XMLSchema#string

Raed A Dweik

http://www.w3.org/2001/XMLSchema#string

P2860

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion.

Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion.

ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American Coll

Prostanoid therapy for pulmonary arterial hypertension.

Updated evidence-based treatment algorithm in pulmonary arterial hypertension.

Anesthetic management of patients with pulmonary hypertension.

Reference equations for the six-minute walk in healthy adults.

Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.

Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension.

P304

4-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/FJC.0000000000000018

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Adriano R. Tonelli

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24084219

http://www.w3.org/2001/XMLSchema#string

P932

4662283

http://www.w3.org/2001/XMLSchema#string

Subcutaneous to intravenous prostacyclin analog transition in pulmonary hypertension

about

P2860

P2860

Subcutaneous to intravenous prostacyclin analog transition in pulmonary hypertension

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932